Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
54.31
+0.08 (0.15%)
At close: Nov 21, 2025, 4:00 PM EST
54.84
+0.53 (0.98%)
After-hours: Nov 21, 2025, 7:57 PM EST
Akero Therapeutics Employees
Akero Therapeutics had 63 employees as of December 31, 2024. The number of employees increased by 7 or 12.50% compared to the previous year.
Employees
63
Change (1Y)
7
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$4,647,937
Market Cap
4.47B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63 | 7 | 12.50% |
| Dec 31, 2023 | 56 | 17 | 43.59% |
| Dec 31, 2022 | 39 | 5 | 14.71% |
| Dec 31, 2021 | 34 | 12 | 54.55% |
| Dec 31, 2020 | 22 | 8 | 57.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKRO News
- 1 day ago - Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO - Business Wire
- 9 days ago - Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - PRNewsWire
- 14 days ago - Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 4 weeks ago - My Top 3 Pharma Stocks - Seeking Alpha
- 6 weeks ago - Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX - Seeking Alpha
- 6 weeks ago - Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More - Investopedia
- 6 weeks ago - Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug - Fast Company
- 6 weeks ago - Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Benzinga